Cash & Equivalents
Bristol-Myers Squibb Cash & Equivalents decreased by 35.1% to $10.21B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 1.3%, from $10.35B to $10.21B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -6.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase signals improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or aggressive share buybacks.
Detailed definition
Represents the most liquid assets on the balance sheet, including physical currency and short-term investments with matu...
Peer comparison
Large-cap technology peers often maintain high cash balances to fund rapid innovation and offset the cyclical nature of consumer electronics.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.40B | $13.88B | $13.98B | $12.58B | $10.96B | $7.96B | $9.12B | $9.05B | $8.43B | $7.57B | $11.46B | $9.33B | $6.29B | $7.89B | $10.35B | $10.88B | $12.60B | $15.73B | $10.21B |
| QoQ Change | — | +21.8% | +0.7% | -10.0% | -12.9% | -27.4% | +14.7% | -0.8% | -6.9% | -10.2% | +51.5% | -18.6% | -32.6% | +25.4% | +31.1% | +5.1% | +15.9% | +24.8% | -35.1% |
| YoY Change | — | — | — | — | -3.8% | -42.7% | -34.7% | -28.1% | -23.1% | -4.9% | +25.7% | +3.1% | -25.3% | +4.3% | -9.8% | +16.6% | +100.2% | +99.3% | -1.3% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's cash & equivalents?
- Bristol-Myers Squibb (BMY) reported cash & equivalents of $10.21B in Q4 2025.
- How has Bristol-Myers Squibb's cash & equivalents changed year-over-year?
- Bristol-Myers Squibb's cash & equivalents decreased by 1.3% year-over-year, from $10.35B to $10.21B.
- What is the long-term trend for Bristol-Myers Squibb's cash & equivalents?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's cash & equivalents has grown at a -6.8% compound annual growth rate (CAGR), from $14.55B to $10.21B.
- What does cash & equivalents mean?
- Money in the bank and very short-term investments that can be turned into cash almost instantly.